Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer
This is an open label, phase III study evaluating the efficacy and safety of Pyrotinib in Combination With Trastuzumab and paclitaxel in patients HER2 Positive and lymph node negative invasive Breast Cancer
Breast Cancer
DRUG: Pyrotinib|DRUG: Trastuzumab|DRUG: Paclitaxel
Disease free survival, 5 year
distant recurrence free survival, 5 year|overall survival, 5 year|adverse effects, 5 year
This is an open label, phase III study evaluating the efficacy and safety of Pyrotinib in Combination With Trastuzumab and paclitaxel in patients HER2 Positive and lymph node negative invasive Breast Cancer